Emyria Limited (ASX: EMD) Commences National Expansion with Avive in Brisbane - A Mental Health Care Story.
- Noel Ong
- 1 day ago
- 5 min read
Announcement
Emyria Limited (ASX: EMD), a pioneer in evidence-based mental health care, has announced a strategic move into Queensland via a new agreement with Avive Health. This initiative marks the Company’s first Queensland-based clinic and a critical step in Emyria’s nationwide expansion strategy. The new clinic, to be located within Avive’s licensed 63-bed mental health hospital in Brisbane, will house an Empax Centre focused on treatment-resistant depression and Post-traumatic stress disorder (PTSD).
Figure 1: The Avive mental health hospital in Brisbane features a 63-bed facility that combines a restored heritage-listed exterior with a modern, welcoming interior reception area. (source: EMD)
This announcement follows closely on the heels of Emyria’s landmark reimbursement agreement with Medibank Private Ltd (ASX: MPL), underscoring a growing demand for reimbursable, specialised mental health treatments. The Brisbane clinic is expected to begin operations in Q4 CY2025, subject to approvals and fit-out completion.
1. Key Highlights - The Care for Mental Health Solution.
✅ Landmark Agreement: Emyria has secured an exclusive deal with Avive Health to launch its first Empax clinic in Queensland, specifically within Avive’s licensed Brisbane hospital.
✅ First Right of Refusal: The agreement includes first rights to expand into Avive-operated hospitals in Victoria and South Australia, supporting further national rollout.
✅ Capital-Light Expansion Model: Avive provides infrastructure and licensure, while Emyria delivers the full clinical team and Empax programs, enabling cost-effective scaling.
✅ Strategic Fit: This initiative aligns with Emyria’s Medibank agreement to deliver reimbursed psychedelic-assisted therapy and addresses high unmet needs in PTSD and treatment-resistant depression.
✅ Strong Demand & Timeline: The Brisbane clinic is expected to significantly expand patient capacity, with treatments to commence in late 2025.
2. Strategic Rationale and National Expansion Vision
Mental health remains one of Australia’s most pressing chronic conditions, with PTSD affecting approximately 1 in 11 Australians and disproportionately impacting women, veterans, and first responders. Emyria’s Empax program responds to this demand with a scalable, clinically validated model that delivers real-world care while capturing actionable data to inform future therapies.
This expansion into Brisbane is a major step in Emyria’s broader strategy, which includes:
Opening additional Empax centres in major Eastern states.
Partnering with hospital networks and insurers to support access and affordability.
Expanding indications beyond PTSD and TRD.
Leveraging real-world data to support regulatory and payer engagement.
The partnership with Avive allows Emyria to embed its Empax protocols directly into Avive’s hospital systems, supporting integrated, high-quality care delivery.
Greg Hutchinson, Emyria’s Executive Chairman, commented:
“This agreement with Avive is a key milestone in our east coast expansion strategy and allows us to bring our innovative Empax model of care to patients in Queensland. Our recent agreement with Medibank was the first of its kind and strong validation of our approach, and we are now building on that momentum to expand patient access to funded, innovative mental health care, nationally.”
Mark Sweeney, Co-CEO of Avive, added:
“Avive is committed to becoming Australia’s leading provider of innovative, high-quality mental health care. This partnership with Emyria and the establishment of an Empax Centre within our Brisbane facility reflects our ambition to integrate cutting-edge treatments into our service offering.”
Samso Concluding Comments
The agreement with Avive represents more than just geographic expansion—it affirms the robustness of Emyria’s scalable, capital-efficient model. With infrastructure costs largely offset through partnerships, the Company continues to extend its clinical footprint without compromising its balance sheet. This is particularly important in the current investment climate, where capital preservation is as important as growth.
For investors, Emyria’s positioning within the reimbursed mental health space, particularly through novel psychedelic-assisted therapies, sets it apart from traditional healthcare players. The alignment with a trusted insurer (Medibank) and now a growing hospital operator (Avive) brings commercial credibility to its strategy.
As the mental health crisis in Australia intensifies, Emyria’s ability to provide structured, data-backed, reimbursable care gives it a real-world advantage. The forward momentum—clinically, commercially, and geographically—is clear.
The Company is building its growth through deliberate partnerships and evidence-based protocols. For investors tracking next-generation healthcare platforms, Emyria offers an intriguing combination of innovation, execution, and early-stage traction.
The Samso Way – Seek the Research
At Samso, we encourage readers to engage deeply with Emyria’s strategic evolution. The mental health space is not only a humanitarian priority but also a sector poised for sustained investment attention. The Company’s investor hub and consistent ASX updates offer ample transparency—do the research, ask questions, and stay informed.
Our mission is simple: cut through the noise and spotlight what matters—genuine stories, grounded insights, and real opportunity.
Our content is well-researched and is only created if the team sees a merit in discussing the company or concept. Investors can explore our three core platforms:
There may be numerous paths to success in investing, but the common thread among successful individuals is that they remain committed to making informed decisions. Equip yourself with the right knowledge and tools, and you will be well on your way to achieving your financial goals.
Most importantly, investors need to be absolutely diligent in understanding their own risk-reward tolerance and capabilities. Never bite off more than you can chew. As they say, Rome wasn’t built in a day, and the Great Wall stood because it took centuries to complete.
The Samso Philosophy:
Stay curious. Stay sharp. And remember—digging deeper always uncovers the real value.
In Life, there is no such thing as a Free Lunch.
Happy Investing, and the only four-letter word you need to know is DYOR.
To support our independent nature of our work, please head over to our Support Page and give us a helping hand in any of the ways listed. This is a new initiate for the Samso Platform, and it was always the concept of Samso when we started this journey in 2018.
Disclaimer
The information or opinions provided herein do not constitute investment advice, an offer or solicitation to subscribe for, purchase or sell the investment product(s) mentioned herein. It does not take into consideration, nor have any regard to your specific investment objectives, financial situation, risk profile, tax position and particular, or unique needs and constraints.
Share to Grow: Your Bonus
Samso has just released an eBook: How to Add Value to your Share Portfolio
A lesson on geological models sought by mining companies that gives insight and an understanding of which portfolios are better - and potentially more lucrative – investments. Click here to download this eBook.
If you find this article informative and useful, please help me share the information. I try and write about topics that are interesting and have the potential to be of investment value. It is not easy to find stories that fit those parameters. If you or your organisation see the benefit of what Samso is trying to achieve and have a need to share your journey, please contact me at noel.ong@samso.com.au.
Samso is a trusted platform that equips dedicated investors with up-to-date industry knowledge and insights from top CEOs and thought leaders. By staying informed on business advancements and market trends, investors can enhance their financial decisions through a combination of expert guidance and their own research.